News
Vybion receives grant award from NIH
December 3, 2009
Vybion receives grant award from NIH for “Rapid Isolation of High Affinity Human Antibodies from Large Synthetic Libraries”. The $200,000 grant is part of the ongoing collaboration with Dr. Matthew DeLisa at Cornell University. The grant further develops Vybion’s ProCode antibody drug discovery platform to fulfill its commercial potential.
Lee Henderson, Ph.D. to give presentation at PepCon Conference
November 1, 2009
Lee Henderson, Ph.D. was invited to give a presentation at the PepCon Conference in Beijing, China in late March. Dr. Henderson will focus his presentation on the ProCode antibody discovery and engineering platform.
Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic
properties of biologics
July 2009
Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic properties of biologics. Vybion’s pegylation technology is up to 70% efficiency and >99% specificity on a single amino acid. Increased circulating half lives of over 10 fold (less than one day to 10 days) have been demonstrated in animal models. Vybion’s NPEG technology will be used in the development of antibody-like drugs with Vybion’s ProCode technology and is available for partnering and out-licensing.
Vybion receives $1.3M subcontract to develop diagnostics for Lassa Virus
Jun 10, 2009
Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. Researchers at Tulane University, in collaboration with Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, have received a five-year $7.07 million grant from the National Institutes of Health (NIH) for continued development of detection kits for Lassa viral hemorrhagic fever, a serious disease spread by contact with infected rodents. Viral hemorrhagic fevers are characterized by fever and bleeding disorders and can progress to high fever and shock. Lassa fever is estimated to infect 300,000 to 500,000 people per year across West Africa, resulting in approximately 5,000 deaths.
This is the second grant awarded to Tulane for Lassa virus products. Also collaborating with Corgenix and Tulane in this grant are Autoimmune Technologies, LLC ( New Orleans), Vybion, Inc. (Ithaca, NY), and various partners in West Africa.
Read full story »
Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board
October 1, 2008
Ithaca, October 1 -- Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. Matthew DeLisa, Ph.D. is on the faculty of Cornell University in the Department of Chemical and Molecular Engineering and the inventor of ProCode. DeLisa’s research group combines protein engineering with genetic and molecular biology approaches to address fundamental issues related to protein transport, protein folding and solubility, and protein synthesis. William Ball, Ph.D. is a member of the Department of Pharmacology and Cell Biophysics while Andrew Norman, Ph.D. is in the Department of Psychiatry and is Director of the Division of Neuroscience at the University of Cincinnati. Drs. Norman and Ball are the developers of CoMab, a high affinity antibody to cocaine. Drs. Norman and Ball have a longstanding interest in addiction therapies and the physiology of drug interactions.
Corgenix Announces Expansion of Hemorrhagic Fever Virus Product Development Program
Jul 10, 2008
Denver, July 10 -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an expansion of the collaborative effort for developing test kits for viral hemorrhagic fever (VHF) detection... Joining the collaboration is Vybion, Inc., an Ithaca, N.Y., based biotechnology company. Vybion CEO Lee Henderson, Ph.D., stated, "We are pleased to be able to work with Corgenix, Tulane and the other partners. With our deep experience in protein expression from bacterial and mammalian cells and our extensive technology portfolio, we will be able to provide the commercial scale-up for the recombinant protein efforts." Read full Routers story »
Vybion Awarded Monoclonal Antibody Development Contract.
April 11, 2007
Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes, developing the expression lines and the process for manufacturing the product. The antibody, specific for cocaine, binds cocaine in the blood stream, causing cocaine in brain tissues to cross the blood brain barrier back into the blood where it remains bound to the antibody prior to detoxification in liver. More (4KB) »
Vybion Licenses ProCode™ Platform
January 22, 2007
Ithaca, NY: Vybion has exclusively licensed a drug development platform from Cornell University. The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs. ProCode offers several important advantages that strongly differentiate it from other technologies including dramatic reductions in drug development time, cost, and ease of use. More (5KB) »
Vybion Presents at PepTalk Conference
January 8, 2007
Vybion CEO, Lee Henderson, Ph.D., made a poster presentation at the annual PepTalk Conference in San Diego on the ProCode Technology with work done by Matthew DeLisa, Ph.D. and his group in the Department of Chemical and Molecular Engineering at Cornell University. The poster centered on the applications of the ProCode twin arginine transport system for affinity improvement of monoclonal antibodies and solubility improvement of a variety of biologics. Several examples of the technology were presented. ProCode is a Platform technology for drug development that saves time, cost and is easy to use as well.
